發(fā)布時(shí)間：2018-02-27 16:35

  本文關(guān)鍵詞： 精神分裂癥 認(rèn)知功能 多奈哌齊　出處：《中南大學(xué)》2012年碩士論文　論文類型：學(xué)位論文

【摘要】：目的 探討抗精神病藥合并膽堿酯酶抑制劑多奈哌齊對(duì)精神分裂癥患者認(rèn)知功能的療效。 研究方法 本研究采用隨機(jī)雙盲安慰劑對(duì)照的方法,56例穩(wěn)定期精神分裂癥患者隨機(jī)分為抗精神病藥合并多奈哌齊組(研究組,28例)和抗精神病藥合并安慰劑組(對(duì)照組,28例),在原有抗精神病藥物的基礎(chǔ)上分別加用多奈哌齊(5mg/d)或安慰劑口服治療,治療12周。于治療基線及治療12周末進(jìn)行認(rèn)知功能(包括處理速度、言語學(xué)習(xí)及記憶、視覺學(xué)習(xí)及記憶、工作記憶、注意警覺、執(zhí)行功能六個(gè)緯度)、精神癥狀(陽性與陰性癥狀量表,the Positive and Negative Syndrome Scale PANSS)、社會(huì)功能(個(gè)人與社會(huì)表現(xiàn)量表,Personal and Social Performance, PSP)及不良反應(yīng)評(píng)估,主要評(píng)估指標(biāo)為認(rèn)知功能及陰性癥狀。 結(jié)果 1.治療12周末與基線相比,多奈哌齊組的處理速度、視覺學(xué)習(xí)和記憶、工作記憶測(cè)驗(yàn)成績均有顯著改善(P0.05)；PSP總分改善顯著(P0.05)；PANSS總分及陰性癥狀分量表分無顯著變化(P0.05)： 2.治療12周末與基線相比,安慰劑組在認(rèn)知功能測(cè)驗(yàn)成績均無顯著改善；PSP總分、PANSS總分及其陰性癥狀分量表分無顯著變化(P0.05)； 3.兩組改善值比較,多奈哌齊組在認(rèn)知功能的處理速度、視覺學(xué)習(xí)和記憶、工作記憶方面顯著優(yōu)于安慰劑組(P0.05)；PSP總分改善、PANSS總分及其陰性癥狀分量表分變化值兩組無顯著差異(P0.05)： 4.不良反應(yīng)的發(fā)生率兩組差異無統(tǒng)計(jì)學(xué)意義(P0.05),未發(fā)生嚴(yán)重不良反應(yīng)。 結(jié)論 1.抗精神病藥合并多奈哌齊可以改善病情穩(wěn)定期精神分裂癥患者的處理速度、視覺學(xué)習(xí)和記憶、工作記憶等認(rèn)知功能； 2.抗精神病藥合并多奈哌齊具有良好的臨床用藥安全性。
[Abstract]:Purpose. To investigate the effect of antipsychotic drugs combined with cholinesterase inhibitor Donepezil on cognitive function in patients with schizophrenia. Research method. In this study, 56 patients with stable schizophrenia were randomly divided into two groups: antipsychotics combined with Donepezil (study group, 28 cases) and antipsychotics combined with placebo (control group, n = 28). On the basis of the original antipsychotic drugs, they were treated orally with Donepezil 5 mg / d or placebo, respectively. 12 weeks of treatment. Cognitive function (including processing speed, speech learning and memory, visual learning and memory, working memory, attention alertness) is performed at baseline and 12 weeks of treatment. Six dimensions of executive function, the Positive and Negative Syndrome Scale PANSSN, the personal and Social performance (PSPs) and the adverse reactions were evaluated. The main evaluation indexes were cognitive function and negative symptoms. Results. 1.Compared with the baseline at the end of 12 years, the scores of processing speed, visual learning and memory, working memory test in the Donepezil group were significantly improved. The total score of P0.05 and PSP were significantly improved. There was no significant change in the total score of PANSS and the subscale of negative symptoms in the group of Donepezil (P 0.05). 2.Compared with baseline at the end of 12 years, the scores of cognitive function test in placebo group were not significantly improved, the total score of PSP and the total score of PANSS and the subscale of negative symptoms had no significant change (P 0.05). 3.Compared with the improvement values of the two groups, there was no significant difference between the two groups in the processing speed of cognitive function, visual learning and memory, working memory and the total score of PSP in placebo group. There was no significant difference between the two groups in improving the total score of PANSS and its negative symptom subscale (P 0.05). 4. There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). Conclusion. 1. Antipsychotic drugs combined with Donepezil can improve the cognitive function, such as processing speed, visual learning and memory, working memory and so on; 2. Antipsychotic drugs combined with Donepezil have good clinical safety.
【學(xué)位授予單位】：中南大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2012
【分類號(hào)】：R749.3

【參考文獻(xiàn)】

相關(guān)期刊論文 前2條

1 行養(yǎng)玲!710061,楊旭!710061,董群惠!710061,紀(jì)術(shù)茂!710061,韓德!710061;首發(fā)精神分裂癥患者認(rèn)知功能研究[J];臨床精神醫(yī)學(xué)雜志;1999年06期

2 劉建新;多巴胺受體與精神分裂癥關(guān)系的研究現(xiàn)狀[J];國外醫(yī)學(xué).臨床生物化學(xué)與檢驗(yàn)學(xué)分冊(cè);2003年04期

，

本文編號(hào)：1543462